Sign up
Pharma Capital

AngioDynamics’ stock tumbles after fiscal 4Q earnings miss on lukewarm revenue

The New York-based medical device company also forecast fiscal 2019 earnings that underwhelmed analysts
Doctors performing an operation
AngioDynamics said it would focus on its portfolio optimization strategy

Shares of AngioDynamics Inc. (NASDAQ:ANGO) tumbled Wednesday after the medical-device company reported fiscal fourth-quarter earnings that missed Wall Street expectations.

AngioDynamics' stock plunged nearly 11.12% to US$20.07.

The Latham, New York-based company which sells surgical and diagnostic devices for the treatment of peripheral vascular disease, posted earnings of US$0.20 per share on revenue of US$88.3mln. This missed the consensus earnings estimate for US$0.21 per share on revenue of US$89mln.

The company said it would persevere with the areas which contributed to consistent “cash flow generation.”  

“Our oncology ablation systems, AngioVac thrombus management product, and Fluid Management family of products are each examples of where we are well positioned to win and grow the value of the company,” said AngioDynamics CEO Jim Clemmer.

“We will continue to actively focus on pursuing our portfolio optimization strategy, which includes both internal and external growth opportunities. We will look to augment those areas where we currently have a product family foundation with additional opportunities to win, driving sustainable long-term revenue growth.”

Forward guidance

The company said it expects fiscal 2019 earnings of US$0.82 to US$0.86 per share on revenue of US$344mln to US$349mln.

The current consensus earnings estimate is pegged at US$0.93 per share on revenue of US$347.6mln for the year ending May 31, 2019.

Contact Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive



Register here to be notified of future ANGO Company articles
View full ANGO profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.